Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 6 Results

Title
Intervention Indication Therapeutic Area Year Actions
ALXN 1210 for Paroxysmal Nocturnal Haemoglobinuria – First Line Ravulizumab (ALXN1210; Ultomiris) Paroxysmal nocturnal haemoglobinuria (PNH) Haematology 2017 View  |  Download
Danicopan with eculizumab or ravulizumab for treating paroxysmal nocturnal haemoglobinuria Danicopan (ACH-0144471; ACH-4471; ALXN2040) , Ravulizumab (ALXN1210; Ultomiris) Paroxysmal nocturnal haemoglobinuria (PNH) Haematology 2022 View  |  Download
Ravulizumab for atypical haemolytic uraemic syndrome in adults and children – first line Ravulizumab (ALXN1210; Ultomiris) Atypical haemolytic uraemic syndrome (aHUS) Haematology , Nephrology 2018 View  |  Download
Ravulizumab for paroxysmal nocturnal haemoglobinuria in paediatrics Ravulizumab (ALXN1210; Ultomiris) Paroxysmal nocturnal haemoglobinuria (PNH) Haematology 2021 View  |  Download
Ravulizumab for treating generalised myasthenia gravis Ravulizumab (ALXN1210; Ultomiris) Myasthenia gravis (MG) Musculoskeletal System 2021 View  |  Download
Ravulizumab for treatment of neuromyelitis optica spectrum disorder Ravulizumab (ALXN1210; Ultomiris) Neuromyelitis optica spectrum disorders Nephrology , Ophthalmology 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications